Top-Rated StocksTop-RatedNASDAQ:TNDM Tandem Diabetes Care (TNDM) Stock Price, News & Analysis $39.15 -0.30 (-0.76%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$38.58▼$39.8250-Day Range$35.12▼$53.4352-Week Range$13.82▼$53.69Volume1.29 million shsAverage Volume1.73 million shsMarket Capitalization$2.53 billionP/E RatioN/ADividend YieldN/APrice Target$51.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Tandem Diabetes Care alerts: Email Address Tandem Diabetes Care MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside30.9% Upside$51.25 Price TargetShort InterestBearish13.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment1.54Based on 4 Articles This WeekInsider TradingSelling Shares$258,400 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.71) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.39 out of 5 starsMedical Sector113th out of 914 stocksSurgical & Medical Instruments Industry17th out of 98 stocks 4.5 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTandem Diabetes Care has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tandem Diabetes Care's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.62% of the outstanding shares of Tandem Diabetes Care have been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Tandem Diabetes Care has recently decreased by 3.61%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTandem Diabetes Care has received a 80.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Tandem Diabetes Care is -0.64. Previous Next 2.5 News and Social Media Coverage News SentimentTandem Diabetes Care has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tandem Diabetes Care this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,400.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Tandem Diabetes Care is held by insiders.Read more about Tandem Diabetes Care's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow in the coming year, from ($1.71) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -18.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -18.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 8.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tandem Diabetes Care's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsAI depends on this... Your retirement could too!Imagine owning a piece of the backbone powering the AI revolution. Wall Street says it's extremely undervalued - a downright steal compared to peers. We call it the "Last Retirement Stock You'll Ever Need."Get all the urgent details here >>> About Tandem Diabetes Care Stock (NASDAQ:TNDM)Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Read More TNDM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNDM Stock News HeadlinesJune 4, 2024 | insidertrades.comDick Allen Sells 5,000 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) StockJune 29, 2024 | americanbankingnews.comFinancial Comparison: Plus Therapeutics (NASDAQ:PSTV) & Tandem Diabetes Care (NASDAQ:TNDM)July 3, 2024 | Behind the Markets (Ad)Major Pharma Deals Propel This Undervalued AI StockYou need to check out this game-changing biotech stock. Their physics-based software can model how molecules behave and identify ideal drug candidates in record time. Big Pharma is taking notice.June 26, 2024 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Shares Down 4.2% June 22, 2024 | businesswire.comTandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific SessionsJune 20, 2024 | businesswire.comTandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating OfficerJune 19, 2024 | investorplace.comThe 3 Best Diabetes Stocks to Buy in June 2024June 18, 2024 | businesswire.comTandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association's 84th Scientific SessionsJuly 3, 2024 | Behind the Markets (Ad)Major Pharma Deals Propel This Undervalued AI StockYou need to check out this game-changing biotech stock. Their physics-based software can model how molecules behave and identify ideal drug candidates in record time. Big Pharma is taking notice.May 29, 2024 | businesswire.comTandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGMMay 23, 2024 | finance.yahoo.comTandem Diabetes Care Announces Upcoming Conference PresentationMay 23, 2024 | businesswire.comTandem Diabetes Care Announces Upcoming Conference PresentationMay 22, 2024 | msn.comCitigroup Upgrades Tandem Diabetes Care (TNDM)May 15, 2024 | msn.comEminence Capital's Q1 moves include adding MNDY, J, exiting SCHW, FROGMay 12, 2024 | msn.comFDA issues 'most serious type of recall' for insulin pump-related iOS appMay 7, 2024 | msn.comTandem Diabetes Care GAAP EPS of -$0.65 beats by $0.12, revenue of $191.67M beats by $18.13MMay 6, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)May 5, 2024 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target To US$43.57May 3, 2024 | fool.comWhy Tandem Diabetes Stock Just Jumped 22%May 3, 2024 | finance.yahoo.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketwatch.comTandem Diabetes Care Shares Rise 17% on Raised 2024 Sales OutlookMay 3, 2024 | finance.yahoo.comTandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 3, 2024 | finance.yahoo.comQ1 2024 Tandem Diabetes Care Inc Earnings CallMay 2, 2024 | investorplace.comTNDM Stock Earnings: Tandem Diabetes Care Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | businesswire.comTandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial GuidanceMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)April 30, 2024 | msn.comWells Fargo Upgrades Tandem Diabetes Care (TNDM)See More Headlines Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TNDM CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone(858) 366-6900FaxN/AEmployees2,400Year Founded2006Price Target and Rating Average Stock Price Target$51.25 High Stock Price Target$75.00 Low Stock Price Target$34.00 Potential Upside/Downside+30.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-222,610,000.00 Net Margins-18.37% Pretax Margin-17.69% Return on Equity-34.38% Return on Assets-10.91% Debt Debt-to-Equity Ratio1.43 Current Ratio3.81 Quick Ratio3.01 Sales & Book Value Annual Sales$747.72 million Price / Sales3.38 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book8.14Miscellaneous Outstanding Shares64,590,000Free Float63,169,000Market Cap$2.53 billion OptionableOptionable Beta1.28 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. John F. Sheridan (Age 69)President, CEO & Director Comp: $988.35kMs. Leigh A. Vosseller (Age 50)Executive VP, CFO & Treasurer Comp: $543.38kMs. Susan M. Morrison (Age 45)Executive VP & Chief Administrative Officer Comp: $538.21kMr. David B. Berger Esq. (Age 54)Transitional Advisor Comp: $543.38kMr. Brian B. Hansen (Age 56)Executive Officer Comp: $561.74kMs. Elizabeth Anne Gasser (Age 48)Executive Vice President and Chief Strategy & Product Officer Comp: $542.91kMr. Mark Novara (Age 49)Executive VP & Chief Commercial Officer Comp: $169.6kMr. Rick A. Carpenter (Age 61)Chief Technical Officer Ms. Shannon M. Hansen (Age 58)Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary Mr. Tom FoxChief Human Resources OfficerMore ExecutivesKey CompetitorsTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDSolventumNYSE:SOLVPenumbraNYSE:PENGlaukosNYSE:GKOSView All CompetitorsInsiders & InstitutionsGAMMA Investing LLCBought 431 shares on 7/2/2024Ownership: 0.007%Dick AllenSold 5,000 sharesTotal: $258,400.00 ($51.68/share)Comerica BankSold 3,322 shares on 5/17/2024Ownership: 0.048%Walleye Trading LLCSold 38,600 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 3,472 shares on 5/16/2024Ownership: 0.101%View All Insider TransactionsView All Institutional Transactions TNDM Stock Analysis - Frequently Asked Questions Should I buy or sell Tandem Diabetes Care stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TNDM shares. View TNDM analyst ratings or view top-rated stocks. What is Tandem Diabetes Care's stock price target for 2024? 13 analysts have issued 12-month price targets for Tandem Diabetes Care's stock. Their TNDM share price targets range from $34.00 to $75.00. On average, they predict the company's stock price to reach $51.25 in the next year. This suggests a possible upside of 30.9% from the stock's current price. View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts. How have TNDM shares performed in 2024? Tandem Diabetes Care's stock was trading at $29.58 on January 1st, 2024. Since then, TNDM shares have increased by 32.4% and is now trading at $39.15. View the best growth stocks for 2024 here. When is Tandem Diabetes Care's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TNDM earnings forecast. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings data on Thursday, May, 2nd. The medical device company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.17. The medical device company earned $191.67 million during the quarter, compared to analyst estimates of $173.06 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative trailing twelve-month return on equity of 34.38%. What ETFs hold Tandem Diabetes Care's stock? ETFs with the largest weight of Tandem Diabetes Care (NASDAQ:TNDM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Health Care AlphaDEX Fund (FXH), Fidelity Disruptive Medicine ETF (FMED) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC). When did Tandem Diabetes Care's stock split? Tandem Diabetes Care shares reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care issued an update on its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $205.0 million-$205.0 million, compared to the consensus revenue estimate of $205.0 million. What is John Sheridan's approval rating as Tandem Diabetes Care's CEO? 11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL). Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by a number of institutional and retail investors. Top institutional shareholders include GAMMA Investing LLC (0.01%). Insiders that own company stock include Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, Rebecca B Robertson, Shannon Marie Hansen and Susan Morrison. View institutional ownership trends. How do I buy shares of Tandem Diabetes Care? Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNDM) was last updated on 7/3/2024 by MarketBeat.com Staff From Our PartnersWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredYour bank account could be compromisedPlease read this message carefully … Because your money could be at risk.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tandem Diabetes Care With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.